Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...

Schneider Electric and JLL examine nine measures that could help healthcare organizations save money and reduce carbon dioxide emissions as they upgrade their infrastructure.

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD programPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CELMoD--Bristol ...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by ...

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

The Cybernetics Association (UG) and Technophite Association (PG) of the School of IT of St Joseph’s University, Bengaluru hosted SYNTAXIA 2026, a vibrant National Inter-College Technical Fest, on ...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinic ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.

FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...

Constellation Software Inc. ( CSU:CA) Q4 2025 Earnings Call March 9, 2026 8:30 AM EDT Good morning, and welcome to Constellation Software's 2025 Fourth Quarter Results. [Operator Instructions]. Please ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...